



WITHDRAWN STUDY STATEMENT

Sponsor: Teva Pharmaceutical Industries, Ltd.

Title of Study: An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 µg/kg and 670 µg/kg in pediatric patients diagnosed with solid tumors receiving chemotherapy.

Study Number: NEUGR-005

EudraCT Number: 2012-005432-28

Investigational Product: Balugrastim

Phase: 2

Statement: This study was registered in the EudraCT database. However, the study was approved but never started. The study ended prior to any recruitment activity due to an internal business decision. No participants were enrolled, therefore, no results are available.